Persistent Asset Partners Ltd Buys Shares of 69,441 Edgewise Therapeutics, Inc. $EWTX

Posted by Francis Steltz on Aug 17th, 2026

Persistent Asset Partners Ltd bought a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 69,441 shares of the company’s stock, valued at approximately $2,821,000. Edgewise Therapeutics comprises 0.8% of Persistent Asset Partners Ltd’s investment portfolio, making the stock its 23rd largest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Orbimed Advisors LLC increased its position in Edgewise Therapeutics by 3.3% during the 2nd quarter. Orbimed Advisors LLC now owns 15,518,492 shares of the company’s stock valued at $203,447,000 after buying an additional 496,771 shares in the last quarter. RA Capital Management L.P. boosted its holdings in Edgewise Therapeutics by 5.3% in the third quarter. RA Capital Management L.P. now owns 10,428,437 shares of the company’s stock worth $169,149,000 after acquiring an additional 525,804 shares in the last quarter. Paradigm Biocapital Advisors LP grew its stake in shares of Edgewise Therapeutics by 6.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,541,210 shares of the company’s stock worth $162,320,000 after acquiring an additional 371,079 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Edgewise Therapeutics by 29.5% in the first quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company’s stock worth $186,289,000 after acquiring an additional 1,348,706 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Edgewise Therapeutics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 4,871,624 shares of the company’s stock worth $120,889,000 after acquiring an additional 67,683 shares during the last quarter.

Insider Buying and Selling

In related news, CEO Kevin Koch sold 17,971 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.68, for a total value of $784,973.28. Following the transaction, the chief executive officer directly owned 52,488 shares of the company’s stock, valued at approximately $2,292,675.84. This trade represents a 25.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Joanne M. Donovan sold 2,919 shares of Edgewise Therapeutics stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $43.41, for a total value of $126,713.79. Following the transaction, the chief marketing officer owned 8,625 shares in the company, valued at $374,411.25. This trade represents a 25.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 238,329 shares of company stock valued at $9,557,529. Company insiders own 21.30% of the company’s stock.

Edgewise Therapeutics Stock Performance

EWTX opened at $44.17 on Monday. The company’s 50 day moving average is $40.12 and its 200 day moving average is $34.66. The company has a market cap of $4.80 billion, a price-to-earnings ratio of -23.88 and a beta of 0.30. Edgewise Therapeutics, Inc. has a 12-month low of $13.52 and a 12-month high of $48.40.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.06). As a group, analysts predict that Edgewise Therapeutics, Inc. will post -2.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Evercore reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Edgewise Therapeutics in a research report on Monday, July 20th. Truist Financial set a $52.00 price objective on shares of Edgewise Therapeutics in a research report on Wednesday, May 6th. Guggenheim increased their price objective on shares of Edgewise Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Raymond James Financial restated a “strong-buy” rating and set a $66.00 price objective on shares of Edgewise Therapeutics in a research note on Monday, June 1st. Finally, Royal Bank Of Canada lifted their target price on shares of Edgewise Therapeutics from $48.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Edgewise Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $49.08.

Check Out Our Latest Report on EWTX

Trending Headlines about Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

Neutral Sentiment: The sales were made to cover tax-withholding obligations associated with the vesting of equity awards, rather than representing stated concerns about the company’s outlook. Insiders continued to hold shares after the transactions, which reduces the negative significance of the filings. CEO SEC filing General counsel SEC filing Insider SEC filing CMO SEC filing
Negative Sentiment: The number of transactions and the reductions in individual holdings—ranging from roughly 16% to 36%—could create modest sentiment pressure because multiple executives sold shares while EWTX was trading at elevated levels. However, the tax-related purpose makes these filings a limited signal of insider sentiment.

Edgewise Therapeutics Company Profile

(Free Report)

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.